SHINVA(SH:600587) Sou Hu Cai Jing·2026-02-09 11:40Core Viewpoint - Xinhua Medical (600587) has experienced a decline in both revenue and net profit in the first three quarters of 2025, indicating potential challenges in its financial performance [2]. Financial Performance - For the first three quarters of 2025, Xinhua Medical reported a main revenue of 6.978 billion yuan, a year-on-year decrease of 6.0% [2]. - The net profit attributable to shareholders was 434 million yuan, down 29.61% year-on-year [2]. - The net profit after deducting non-recurring items was 370 million yuan, reflecting a significant decline of 38.98% year-on-year [2]. - In Q3 2025, the company recorded a single-quarter main revenue of 2.188 billion yuan, a decrease of 2.2% year-on-year [2]. - The single-quarter net profit attributable to shareholders was approximately 48.59 million yuan, down 63.39% year-on-year [2]. - The single-quarter net profit after deducting non-recurring items was about 37.66 million yuan, a decline of 71.77% year-on-year [2]. - The company's debt ratio stands at 45.85%, with investment income of 48.28 million yuan and financial expenses of 21.30 million yuan [2]. - The gross profit margin is reported at 25.11% [2]. Market Activity - As of February 9, 2026, Xinhua Medical's stock closed at 15.5 yuan, with an increase of 0.78% [1]. - The trading volume was 84,400 hands, with a total transaction amount of 131 million yuan [1]. - On February 9, the net outflow of main funds was 13.21 million yuan, accounting for 10.11% of the total transaction amount [1]. - Retail investors contributed a net inflow of 4.02 million yuan, representing 3.08% of the total transaction amount [1]. - Over the past 90 days, one institution has given a rating of "buy" for the stock, with an average target price of 20.0 yuan [3].